PCSK9 and familial hypercholesterolemia: Hence, gain of function and loss of function mutations in PCSK9 have been found to modulate serum cholesterol levels in humans [25,26,27,28,29] making PCSK9 inhibitors an attractive target to treat hypercholesterolemia in humans [30].